查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1813858

美国胜肽治疗（零售端）市场规模、份额和趋势分析报告：按肽类型、适应症、给药途径、治疗药物类型、分销管道和细分市场进行预测，2025 年至 2033 年

U.S. Peptide Therapeutics (Retail Side) Market Size, Share & Trends Analysis Report By Peptide Type, By Indication, By Route of Administration, By Therapeutics Type, By Distribution Channel, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 165 Pages | 商品交期: 2-10个工作天内

价格

美国胜肽疗法（零售）市场摘要

预计 2024 年美国胜肽疗法（零售）市场规模为 1,036.6 亿美元，到 2033 年将达到 3,361.2 亿美元，2025 年至 2033 年的复合年增长率为 12.77%。

这些疾病在儿童中的发生率不断上升，再加上它们在低收入社区中的广泛发生，凸显了对负担得起且有效的治疗方案的需求。这些疾病在儿童中的发生率不断上升，再加上它们在低收入社区中的广泛发生，凸显了对负担得起且有效的治疗方案的需求。

目录

第一章调查方法与范围

第二章执行摘要

第三章市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场趋势与展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 法律规范
  • 商业环境分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
  • 线上线下通路定价分析
  • 消费者对胜肽疗法的认知趋势
  • 直接面向消费者 (DTC)经营模式的影响

第四章 胜肽类业务分析

  • 美国胜肽治疗学（零售市场）：胜肽类型变化分析
  • 美国胜肽治疗学（零售市场）：胜肽类型细分仪表板
  • 2024 年和 2033 年胜肽类型趋势和市场份额分析
  • 依胜肽类型
  • GLP-1胜肽
  • 健康/长寿/健康生命胜肽
  • 用于其他急性或慢性疾病的胜肽

第五章治疗药物类型业务分析

  • 美国胜肽治疗学（零售市场）：治疗类型的变化分析
  • 美国胜肽疗法（零售市场）：按治疗类型细分仪表板
  • 2024 年和 2033 年治疗类型趋势和市场份额分析
  • 按治疗类型
  • 创新（品牌）胜肽
  • 生物类似胜肽
  • 非专利肽

第六章 指示业务分析

  • 美国胜肽治疗学（零售市场）：适应症波动分析
  • 美国胜肽治疗学（零售市场）：适应症细分仪表板
  • 2024 年和 2033 年适应症趋势和市场份额分析
  • 按指示
  • 2型糖尿病
  • 肥胖/体重管理
  • 神经内分泌肿瘤
  • 肢端肥大症
  • 生长激素缺乏症
  • 摄护腺癌
  • 骨质疏鬆症
  • 乳癌（荷尔蒙敏感性）
  • 子宫内膜异位症
  • 其他的

7. 管理路线业务分析

  • 美国胜肽治疗学（零售市场）：给药途径变化分析
  • 美国胜肽疗法（零售市场）：给药途径细分仪表板
  • 2024 年和 2033 年给药途径趋势和市占率分析
  • 给药途径
  • 口服
  • 肠外
  • 经皮
  • 鼻腔
  • 其他给药途径

第八章通路业务分析

  • 美国胜肽治疗学（零售市场）：分销管道波动分析
  • 美国胜肽治疗（零售）市场：分销通路细分仪表板
  • 2024年及2033年通路趋势与市占率分析
  • 按分销管道
  • 线下药局
    • 线下零售药局市场，2021-2033
    • 连锁药局
    • 专业零售药局
    • 独立社区药房
  • 网路药局/远端医疗
    • 2021-2033年网路药局/远端医疗市场
  • 其他（胜肽专科门诊）

第九章 竞争态势

  • 公司分类（线下药局）
  • 公司分类（网路药局）
  • 公司分类（荷尔蒙诊所）
  • 参与企业概况
    • Offline Pharmacies
    • Online Pharmacies
    • Specialized Hormone Clinics
  • 企业市场分析
  • 战略地图
    • 区域扩张
    • 併购
    • 其他的
  • 公司简介/上市公司
  • Offline Pharmacies
    • CVS Health
    • Walgreens Boots Alliance, Inc.
    • Walmart Pharmacy
    • Rite Aid Corp
    • The Kroger Co.
    • Albertsons
    • Publix
    • Costco Wholesale Corporation
    • Meijer, Inc.
  • Online Pharmacies
    • Hims & Hers Health, Inc
    • Ro (Roman Health Ventures Inc.)
    • Lemonaid Health, Inc.
    • Mark Cuban Cost Plus Drug Company, PBC
    • Amazon.com, Inc.
    • Blink Health Administration LLC, Inc.
    • GoodRx, Inc
    • Honeybee Health Inc.
    • TruePill (acquired by LetsGetChecked in October 2024)
    • AgelessRx
  • Specialized Hormone Clinics
    • Defy Medical
    • Renew Vitality
    • Victory Men's Health
    • Hone Health
    • Joi & Blokes
    • Ways2Well
Product Code: GVR-4-68040-700-6

U.S. Peptide Therapeutics (Retail Side) Market Summary

The U.S. peptide therapeutics (retail side) market size was estimated at USD 103.66 billion in 2024 and is expected to reach USD 336.12 billion by 2033, growing at a CAGR of 12.77% from 2025 to 2033. The increasing number of pediatric patients affected by these conditions, coupled with their widespread occurrence in low-income regions, highlights the need for affordable and effective treatment options. In addition, the increasing number of pediatric patients affected by these conditions, coupled with their widespread occurrence in low-income regions, underscores the need for affordable and effective treatment options.

U.S. Peptide Therapeutics (Retail Side) Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033 For this study, Grand View Research has segmented the U.S. peptide therapeutics (retail side) market report based on peptide type, therapeutics type, indication, route of administration, and distribution channel:

  • Peptide Type Outlook (Revenue, USD Billion, 2021 - 2033)
  • GLP-1 Peptides
  • Wellness/Longevity/Healthspan Peptides
  • Peptides for Other Acute or Chronic Medical Conditions
  • Therapeutics Type Outlook (Revenue, USD Billion, 2021 - 2033)
  • Innovative (Branded) Peptides
  • Biosimilar Peptides
  • Generic Peptides
  • Indication Outlook (Revenue, USD Billion, 2021 - 2033)
  • Type 2 Diabetes
  • Obesity / Weight Management
  • Neuroendocrine Tumors
  • Acromegaly
  • Growth Hormone Deficiency
  • Prostate Cancer
  • Osteoporosis
  • Breast Cancer (hormone-sensitive)
  • Endometriosis
  • Others
  • Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)
  • Parenteral
  • Oral
  • Transdermal
  • Nasal
  • Others
  • Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
  • Offline Retail Pharmacies
    • Chain pharmacies
    • Specialty retail pharmacies
    • Independent community pharmacies
  • Online Pharmacies / Telehealth
  • Others (Specialized Peptide Clinics

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
  • 1.2. Estimates and Forecast Timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
    • 1.4.5. Details of Primary Research
    • 1.4.6. Research Assumption
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Data Visualization
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. Objectives
    • 1.8.1. Objective - 1
    • 1.8.2. Objective - 2
    • 1.8.3. Objective - 3
  • 1.9. List of Secondary Sources
  • 1.10. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. U.S. Peptide Therapeutics (Retail Side) Market
    • 2.1.1. Market Snapshot
    • 2.1.2. Segment Snapshot
      • 2.1.2.1. Therapeutics type & indication segment outlook
      • 2.1.2.2. Route of administration & distribution channel segment outlook
    • 2.1.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
    • 3.3.2. Market Restraint Analysis
  • 3.4. Regulatory Framework
  • 3.5. Business Environment Analysis Tools
    • 3.5.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrant
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL Analysis
  • 3.6. Pricing Analysis in Online vs. Offline Channels
  • 3.7. Consumer Awareness Trends for Peptide Therapies
  • 3.8. Direct-to-Consumer (DTC) Business Models Impact

Chapter 4. Peptide Type Business Analysis

  • 4.1. U.S. Peptide Therapeutics (Retail Side) Market: Peptide Type Movement Analysis
  • 4.2. U.S. Peptide Therapeutics (Retail Side) Market: Peptide Type Segment Dashboard
  • 4.3. Peptide Type Movement & Market Share Analysis, 2024 & 2033
  • 4.4. U.S. Peptide Therapeutics (Retail Side) Market Estimates & Forecast, by Peptide Type
  • 4.5. GLP-1 Peptides
    • 4.5.1. GLP-1 Peptides Market, 2021 - 2033 (USD Million)
  • 4.6. Wellness/Longevity/Healthspan Peptides
    • 4.6.1. Wellness/Longevity/Healthspan Peptides Market, 2021 - 2033 (USD Million)
  • 4.7. Peptides for Other Acute or Chronic Medical Conditions
    • 4.7.1. Peptides for Other Acute or Chronic Medical Conditions Market, 2021 - 2033 (USD Million)

Chapter 5. Therapeutics Type Business Analysis

  • 5.1. U.S. Peptide Therapeutics (Retail Side) Market: Therapeutics Type Movement Analysis
  • 5.2. U.S. Peptide Therapeutics (Retail Side) Market: Therapeutics Type Segment Dashboard
  • 5.3. Therapeutics Type Movement & Market Share Analysis, 2024 & 2033
  • 5.4. U.S. Peptide Therapeutics (Retail Side) Market Estimates & Forecast, by Therapeutics Type
  • 5.5. Innovative (Branded) Peptides
    • 5.5.1. Innovative (Branded) Peptides Market, 2021 - 2033 (USD Million)
  • 5.6. Biosimilar Peptides
    • 5.6.1. Biosimilar Peptides Market, 2021 - 2033 (USD Million)
  • 5.7. Generic Peptides
    • 5.7.1. Generic Peptides Market, 2021 - 2033 (USD Million)

Chapter 6. Indication Business Analysis

  • 6.1. U.S. Peptide Therapeutics (Retail Side) Market: Indication Movement Analysis
  • 6.2. U.S. Peptide Therapeutics (Retail Side) Market: Indication Segment Dashboard
  • 6.3. Indication Movement & Market Share Analysis, 2024 & 2033
  • 6.4. U.S. Peptide Therapeutics (Retail Side) Market Estimates & Forecast, by Indication
  • 6.5. Type 2 Diabetes
    • 6.5.1. Type 2 Diabetes Market, 2021 - 2033 (USD Million)
  • 6.6. Obesity / Weight Management
    • 6.6.1. Obesity / Weight Management Market, 2021 - 2033 (USD Million)
  • 6.7. Neuroendocrine Tumors
    • 6.7.1. Neuroendocrine Tumors Market, 2021 - 2033 (USD Million)
  • 6.8. Acromegaly
    • 6.8.1. Acromegaly Market, 2021 - 2033 (USD Million)
  • 6.9. Growth Hormone Deficiency
    • 6.9.1. Growth Hormone Deficiency Market, 2021 - 2033 (USD Million)
  • 6.10. Prostate Cancer
    • 6.10.1. Prostate Cancer Market, 2021 - 2033 (USD Million)
  • 6.11. Osteoporosis
    • 6.11.1. Osteoporosis Market, 2021 - 2033 (USD Million)
  • 6.12. Breast Cancer (hormone-sensitive)
    • 6.12.1. Breast Cancer (hormone-sensitive) Market, 2021 - 2033 (USD Million)
  • 6.13. Endometriosis
    • 6.13.1. Endometriosis Market, 2021 - 2033 (USD Million)
  • 6.14. Others
    • 6.14.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Route of Administration Business Analysis

  • 7.1. U.S. Peptide Therapeutics (Retail Side) Market: Route of Administration Movement Analysis
  • 7.2. U.S. Peptide Therapeutics (Retail Side) Market: Route of Administration Segment Dashboard
  • 7.3. Route of Administration Movement & Market Share Analysis, 2024 & 2033
  • 7.4. U.S. Peptide Therapeutics (Retail Side) Market Estimates & Forecast, by Route of Administration
  • 7.5. Oral
    • 7.5.1. Oral Market, 2021 - 2033 (USD Million)
  • 7.6. Parenteral
    • 7.6.1. Parenteral Market, 2021 - 2033 (USD Million)
  • 7.7. Transdermal
    • 7.7.1. Transdermal Market, 2021 - 2033 (USD Million)
  • 7.8. Nasal
    • 7.8.1. Nasal Market, 2021 - 2033 (USD Million)
  • 7.9. Other Route of Administration
    • 7.9.1. Other Route of Administration Market, 2021 - 2033 (USD Million)

Chapter 8. Distribution Channel Business Analysis

  • 8.1. U.S. Peptide Therapeutics (Retail Side) Market: Distribution Channel Movement Analysis
  • 8.2. U.S. Peptide Therapeutics (Retail Side) Market: Distribution Channel Segment Dashboard
  • 8.3. Distribution Channel Movement & Market Share Analysis, 2024 & 2033
  • 8.4. U.S. Peptide Therapeutics (Retail Side) Market Estimates & Forecast, by Distribution Channel
  • 8.5. Offline Retail Pharmacies
    • 8.5.1. Offline Retail Pharmacies Market, 2021 - 2033 (USD Million)
    • 8.5.2. Chain Pharmacies
      • 8.5.2.1. Chain Pharmacies Market, 2021 - 2033 (USD Million)
    • 8.5.3. Specialty Retail Pharmacies
      • 8.5.3.1. Specialty Retail Pharmacies market, 2021 - 2033 (USD Million)
    • 8.5.4. Independent Community Pharmacies
      • 8.5.4.1. Specialty Market, 2021 - 2033 (USD Million)
  • 8.6. Online Pharmacies / Telehealth
    • 8.6.1. Online Pharmacies / Telehealth Market, 2021 - 2033 (USD Million)
  • 8.7. Others (Specialized Peptide Clinics)
    • 8.7.1. Others (Specialized Peptide Clinics) Market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization (Offline Pharmacies)
  • 9.2. Company Categorization (Online Pharmacies)
  • 9.3. Company Categorization (Specialized Hormone Clinics)
  • 9.4. Participant's Overview
    • 9.4.1. Offline Pharmacies
    • 9.4.2. Online Pharmacies
    • 9.4.3. Specialized Hormone Clinics
  • 9.5. Company Market Position Analysis
  • 9.6. Strategy Mapping
    • 9.6.1. Regional Expansion
    • 9.6.2. Mergers & Acquisitions
    • 9.6.3. Others
  • 9.7. Company Profiles/Listing
  • 9.8. Offline Pharmacies
    • 9.8.1. CVS Health
      • 9.8.1.1. Overview
      • 9.8.1.2. Financial performance
      • 9.8.1.3. Product benchmarking
      • 9.8.1.4. Strategic initiatives
    • 9.8.2. Walgreens Boots Alliance, Inc.
      • 9.8.2.1. Overview
      • 9.8.2.2. Financial performance
      • 9.8.2.3. Product benchmarking
      • 9.8.2.4. Strategic initiatives
    • 9.8.3. Walmart Pharmacy
      • 9.8.3.1. Overview
      • 9.8.3.2. Financial performance
      • 9.8.3.3. Product benchmarking
      • 9.8.3.4. Strategic initiatives
    • 9.8.4. Rite Aid Corp
      • 9.8.4.1. Overview
      • 9.8.4.2. Financial performance
      • 9.8.4.3. Product benchmarking
      • 9.8.4.4. Strategic initiatives
    • 9.8.5. The Kroger Co.
      • 9.8.5.1. Overview
      • 9.8.5.2. Financial performance
      • 9.8.5.3. Product benchmarking
      • 9.8.5.4. Strategic initiatives
    • 9.8.6. Albertsons
      • 9.8.6.1. Overview
      • 9.8.6.2. Financial performance
      • 9.8.6.3. Product benchmarking
      • 9.8.6.4. Strategic initiatives
    • 9.8.7. Publix
      • 9.8.7.1. Overview
      • 9.8.7.2. Financial performance
      • 9.8.7.3. Product benchmarking
      • 9.8.7.4. Strategic initiatives
    • 9.8.8. Costco Wholesale Corporation
      • 9.8.8.1. Overview
      • 9.8.8.2. Financial performance
      • 9.8.8.3. Product benchmarking
      • 9.8.8.4. Strategic initiatives
    • 9.8.9. Meijer, Inc.
      • 9.8.9.1. Overview
      • 9.8.9.2. Financial performance
      • 9.8.9.3. Product benchmarking
      • 9.8.9.4. Strategic initiatives
  • 9.9. Online Pharmacies
    • 9.9.1. Hims & Hers Health, Inc
      • 9.9.1.1. Overview
      • 9.9.1.2. Financial performance
      • 9.9.1.3. Product benchmarking
      • 9.9.1.4. Strategic initiatives
    • 9.9.2. Ro (Roman Health Ventures Inc.)
      • 9.9.2.1. Overview
      • 9.9.2.2. Financial performance
      • 9.9.2.3. Product benchmarking
      • 9.9.2.4. Strategic initiatives
    • 9.9.3. Lemonaid Health, Inc.
      • 9.9.3.1. Overview
      • 9.9.3.2. Financial performance
      • 9.9.3.3. Product benchmarking
      • 9.9.3.4. Strategic initiatives
    • 9.9.4. Mark Cuban Cost Plus Drug Company, PBC
      • 9.9.4.1. Overview
      • 9.9.4.2. Financial performance
      • 9.9.4.3. Product benchmarking
      • 9.9.4.4. Strategic initiatives
    • 9.9.5. Amazon.com, Inc.
      • 9.9.5.1. Overview
      • 9.9.5.2. Financial performance
      • 9.9.5.3. Product benchmarking
      • 9.9.5.4. Strategic initiatives
    • 9.9.6. Blink Health Administration LLC, Inc.
      • 9.9.6.1. Overview
      • 9.9.6.2. Financial performance
      • 9.9.6.3. Product benchmarking
      • 9.9.6.4. Strategic initiatives
    • 9.9.7. GoodRx, Inc
      • 9.9.7.1. Overview
      • 9.9.7.2. Financial performance
      • 9.9.7.3. Product benchmarking
      • 9.9.7.4. Strategic initiatives
    • 9.9.8. Honeybee Health Inc.
      • 9.9.8.1. Overview
      • 9.9.8.2. Financial performance
      • 9.9.8.3. Product benchmarking
      • 9.9.8.4. Strategic initiatives
    • 9.9.9. TruePill (acquired by LetsGetChecked in October 2024)
      • 9.9.9.1. Overview
      • 9.9.9.2. Financial performance
      • 9.9.9.3. Product benchmarking
      • 9.9.9.4. Strategic initiatives
    • 9.9.10. AgelessRx
      • 9.9.10.1. Overview
      • 9.9.10.2. Financial performance
      • 9.9.10.3. Product benchmarking
      • 9.9.10.4. Strategic initiatives
  • 9.10. Specialized Hormone Clinics
    • 9.10.1. Defy Medical
      • 9.10.1.1. Overview
      • 9.10.1.2. Financial performance
      • 9.10.1.3. Product benchmarking
      • 9.10.1.4. Strategic initiatives
    • 9.10.2. Renew Vitality
      • 9.10.2.1. Overview
      • 9.10.2.2. Financial performance
      • 9.10.2.3. Product benchmarking
      • 9.10.2.4. Strategic initiatives
    • 9.10.3. Victory Men's Health
      • 9.10.3.1. Overview
      • 9.10.3.2. Financial performance
      • 9.10.3.3. Product benchmarking
      • 9.10.3.4. Strategic initiatives
    • 9.10.4. Hone Health
      • 9.10.4.1. Overview
      • 9.10.4.2. Financial performance
      • 9.10.4.3. Product benchmarking
      • 9.10.4.4. Strategic initiatives
    • 9.10.5. Joi & Blokes
      • 9.10.5.1. Overview
      • 9.10.5.2. Financial performance
      • 9.10.5.3. Product benchmarking
      • 9.10.5.4. Strategic initiatives
    • 9.10.6. Ways2Well
      • 9.10.6.1. Overview
      • 9.10.6.2. Financial performance
      • 9.10.6.3. Product benchmarking
      • 9.10.6.4. Strategic initiatives
    • 9.10.7. 4Ever Young Anti-aging Solutions
      • 9.10.7.1. Overview
      • 9.10.7.2. Financial performance
      • 9.10.7.3. Product benchmarking
      • 9.10.7.4. Strategic initiatives
    • 9.10.8. T CLINICS USA
      • 9.10.8.1. Overview
      • 9.10.8.2. Financial performance
      • 9.10.8.3. Product benchmarking
      • 9.10.8.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Market size & forecasts and trend analysis for the therapeutics type segment, 2021 - 2033 (USD Million)
  • Table 4 Market size & forecasts and trend analysis for the indication segment, 2021 - 2033 (USD Million)
  • Table 5 Market size & forecasts and trend analysis for the route of administration segment, 2021 - 2033 (USD Million)
  • Table 6 Market size & forecasts and trend analysis for the distribution channel segment, 2021 - 2033 (USD Million)
  • Table 7 Market size & forecasts and trend analysis for the offline retail pharmacies type segment, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Indication segment snapshot
  • Fig. 10 Route of administration & therapeutics type segment snapshot
  • Fig. 11 Distribution channel segment snapshot
  • Fig. 12 Competitive landscape
  • Fig. 13 U.S. pharmacy market value, 2024 (USD Billion)
  • Fig. 14 U.S. peptide therapeutics (retail side) market dynamics
  • Fig. 15 U.S. peptide therapeutics (retail side) market: Porter's five forces analysis
  • Fig. 16 U.S. peptide therapeutics (retail side) market: PESTLE analysis
  • Fig. 17 U.S. peptide therapeutics (retail side) market therapeutics type outlook: Segment dashboard
  • Fig. 18 U.S. peptide therapeutics (retail side) market: Therapeutics type movement & market share analysis, 2024 & 2033
  • Fig. 19 Innovative (branded) peptides market, 2021 - 2033 (USD Billion)
  • Fig. 20 Generic peptides market, 2021 - 2033 (USD Billion)
  • Fig. 21 Biosimilar peptides market, 2021 - 2033 (USD Billion)
  • Fig. 22 U.S. peptide therapeutics (retail side) market indication outlook: Segment dashboard
  • Fig. 23 U.S. peptide therapeutics (retail side) market: Indication movement & market share analysis, 2024 & 2033
  • Fig. 24 Type 2 diabetes market, 2021 - 2033 (USD Billion)
  • Fig. 25 Obesity/weight management market, 2021 - 2033 (USD Billion)
  • Fig. 26 Prostate cancer market, 2021 - 2033 (USD Billion)
  • Fig. 27 Breast cancer (hormone-sensitive) market, 2021 - 2033 (USD Billion)
  • Fig. 28 Endometriosis market, 2021 - 2033 (USD Billion)
  • Fig. 29 Growth hormone deficiency market, 2021 - 2033 (USD Billion)
  • Fig. 30 Acromegaly market, 2021 - 2033 (USD Billion)
  • Fig. 31 Osteoporosis market, 2021 - 2033 (USD Billion)
  • Fig. 32 Neuroendocrine tumors market, 2021 - 2033 (USD Billion)
  • Fig. 33 Others market, 2021 - 2033 (USD Billion)
  • Fig. 34 U.S. peptide therapeutics (retail side) market route of administration outlook: Segment dashboard
  • Fig. 35 U.S. peptide therapeutics (retail side) market: Route of administration movement & market share analysis, 2024 & 2033
  • Fig. 36 Oral market, 2021 - 2033 (USD Billion)
  • Fig. 37 Parenteral market, 2021 - 2033 (USD Billion)
  • Fig. 38 Transdermal market, 2021 - 2033 (USD Billion)
  • Fig. 39 Nasal market, 2021 - 2033 (USD Billion)
  • Fig. 40 Others market, 2021 - 2033 (USD Billion)
  • Fig. 41 U.S. peptide therapeutics (retail side) market distribution channel outlook: Segment dashboard
  • Fig. 42 U.S. peptide therapeutics (retail side) market: Distribution channel movement & market share analysis, 2024 & 2033
  • Fig. 43 Offline retail pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 44 Chain pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 45 Independent community pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 46 Specialty retail pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 47 Online pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 48 Others (specialized peptide clinics) market, 2021 - 2033 (USD Billion)
  • Fig. 49 Company categorization (Offline Pharmacies)
  • Fig. 50 Company categorization (Online Pharmacy)
  • Fig. 51 Company categorization (Specialized Clinics)
  • Fig. 52 Company market position analysis
  • Fig. 53 Company market position analysis
  • Fig. 54 Company market position analysis
  • Fig. 55 Strategic framework